Year All2024202320222021 Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration 12-27-2023 Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company 11-20-2023 Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results 11-07-2023 Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET 10-31-2023 Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October 10-19-2023 Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director 10-10-2023 Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting 10-05-2023 Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia 10-02-2023 Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference 09-20-2023 Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023 09-09-2023
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration 12-27-2023
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company 11-20-2023
Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET 10-31-2023
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October 10-19-2023
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director 10-10-2023
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia 10-02-2023
Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023 09-09-2023
